top of page

Latest News

We invite you to join us in celebrating our latest groundbreaking achievements in the field!

July 2023

Prof. Sames discusses the interface between academia and entrepreneur activity in the US, our work on ibogaine, and more, for the Czech News outlet FOCUSON (in Czech language)

July 2023

Prof. Sames discusses ibogaine, psychedelics and social and scientific revolutions with Dr. David Hellerstein, physician scientist who runs clinical efficacy studies with psilocybin at Columbia University/NYSPI, on a podcast “Bar Talk Series” YouTube, Spotify

May 2023

Congratulations to Keaon Brown for receiving the "Jack Miller Teaching Award" The Jack Miller awards honor the exceptional teaching skills of graduate students during their second year in the Ph.D. program, paying tribute to the influential nuclear chemist who left a lasting impact through his dedication to teaching and mentoring both undergraduate and graduate students, as well as his colleagues.

May 2023

Congratulations to Priscilla Duggan for receiving the "Capstone Award for Distinguished Achievement" The Capstone Award in Neuroscience is given to a select few Barnard students each year in recognition of the broader impact of their research. This year Priscilla was awarded the title by the Neuroscience Department for Distinguished Achievement in Neuroscience - for the research in our lab.

April 2023

Congratulations to Keaon Brown for passing the second-year defense! 

March 2023

Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease Auxilin participates in clathrin uncoating to facilitate presynaptic endocytosis. Loss-of-function mutations of auxilin (PARK19) cause Parkinson's disease. Using auxilin KO mice, Vidyadhara et al. show that synaptic vesicle sorting deficits, cytoplasmic dopamine accumulation, dopamine transporter mistrafficking, and synaptic autophagic overload may lead to pathogenesis of Parkinson's disease in PARK19 patients.

Dec. 2022

A new paper on Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the alpha-position to the amine. It emerges as a prototype of a new drug class, non-hallucinogenic 5-HT2A agonists, with considerable therapeutic potential across psychiatric and neurological indications. 

Older News Coming Soon!

Please note that this section is currently being updated to include all of our older accomplishments. We apologize for any inconvenience caused and appreciate your patience.

bottom of page